Etter J C, Mayer J M
Klin Monbl Augenheilkd. 1985 Jun;186(6):417-20. doi: 10.1055/s-2008-1050948.
The importance of biopharmaceutics in the development of ophthalmic drugs is pointed out. Ophthalmic drugs have to be stable, sterile, well tolerated and effective. The constraints resulting from these requirements limit the number of pharmaceutical presentations. The development of pilocarpine eye drops is taken as an example to illustrate how difficult it is to satisfy Goldmann's criteria of stability, sterility, tolerance, and efficacy simultaneously. A rapid and sensitive ocular tolerance test for the selection of the most favorable formulations is proposed as a means of counteracting the present shortage of screening tests. Additionally, the physiological, physicochemical, and pharmaceutical factors are discussed which can influence the drugs' passage through the cornea and consequently increase or decrease their efficacy. Two examples, taken respectively from the aqueous solutions and lipophilic gels, demonstrate the importance of pharmaceutical and biological availability as well as the present tendency toward optimization in the development of ophthalmic preparations.
指出了生物药剂学在眼科药物开发中的重要性。眼科药物必须稳定、无菌、耐受性良好且有效。这些要求所带来的限制因素减少了药物剂型的数量。以毛果芸香碱滴眼液的开发为例,来说明同时满足戈德曼关于稳定性、无菌性、耐受性和有效性的标准是多么困难。提出了一种快速且灵敏的眼耐受性试验,用于选择最适宜的制剂,以此来应对目前筛选试验不足的问题。此外,还讨论了可能影响药物透过角膜并进而增加或降低其疗效的生理、物理化学和药剂学因素。分别取自水溶液和亲脂性凝胶的两个例子,证明了药物和生物利用度的重要性以及目前眼科制剂开发中优化的趋势。